このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

An AI-Assisted Agentic System for Ultrasound Scanning and Diagnosis of Ovarian Lesions

2026年9月2日 更新者:Jiale Qin、Women's Hospital School Of Medicine Zhejiang University

New Strategy of Knowledge-Enhanced Large Model for Ultrasound Scanning and Diagnosis of Ovarian Masses

Investigators developed an interactive agentic system designed to guide newly qualified sonographers in ovarian lesion scanning and improve their scanning quality and diagnostic performance toward expert-level standards. Our agentic system is capable of capturing key features including the max-diameter plane of ovarian lesions from dynamic ultrasound videos, translating these findings into standardized International Ovarian Tumor Analysis (IOTA) descriptors, and providing multi-turn guidance for subsequent scanning, and ultimately generating an AI-assisted diagnostic assessment based on embedded expert knowledge.

In this multicenter study, participants are asked to undergo gynecological ultrasonography performed by sonographers with less than 3 years of experience with or without AI assistance. Our researchers will compare the performance of operators working with AI against that of operators working without AI, as well as against the performance of expert sonographers, to see whether AI assistance enhances the proficiency of less experienced operators and help them approach the scanning quality and diagnostic accuracy of expert sonographers in real-world clinical scenarios.

調査の概要

詳細な説明

This multicenter, prospective study will be conducted at tertiary cancer centers and primary healthcare institutions across China. Participants will be recruited from gynecological ultrasound clinics of each site.

Each participant will undergo gynecological ultrasonography under both AI-assisted and unassisted conditions according to their group allocation. Following completion of the study examinations, expert sonographers with more than 10 years of experience, blinded to the scanning and diagnostic results of the junior sonographers, will independently perform a repeat gynecological ultrasound examination of each participant. Based solely on their independent examination, they will issue the final clinical report for each participant. The expert assessments will serve as one reference standard for evaluating scanning completeness, feature interpretation accuracy and diagnostic agreement. Histopathological findings, when available, or clinical follow-up for conservatively managed lesions will serve as the reference standard for evaluating diagnostic accuracy.

研究の種類

観察的

入学 (推定)

250

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Jiale Qin, Prof., Professor
  • 電話番号:+86 0571-89998869
  • メール:qinjiale@zju.edu.cn

研究連絡先のバックアップ

研究場所

    • Zhejiang
      • Hangzhou、Zhejiang、中国、310006
        • Women's Hospital School Of Medicine Zhejiang University
        • コンタクト:
        • コンタクト:
      • Shaoxing、Zhejiang、中国、311800
        • Shaoxing Maternity and Child Health Care Hospital
        • コンタクト:
          • Hua Yuan, Chief physician in ultrasound
          • 電話番号:+86 0575-88211352
          • メール:yh0464@163.com
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

サンプリング方法

非確率サンプル

調査対象母集団

Participants, with suspected ovarian masses identified clinically or by previous imaging examination, will be consecutively recruited from gynecological ultrasound clinics of tertiary cancer centers and primary healthcare institutions across China.

説明

Inclusion Criteria:

  • Female aged 18-75 years
  • With suspected ovarian masses identified clinically or by previous imaging examination
  • Eligible for and able to undergo transvaginal or transabdominal ultrasonography
  • Agree to provide written informed consent before enrollment

Exclusion Criteria:

  • No ovarian mass identified on ultrasound examination
  • Previous bilateral oophorectomy
  • Previous surgery or chemotherapy for ovarian cancer
  • Previous treatment for other malignant tumors
  • Presence of any psychiatric or psychological disorders that may prevent completion of the study procedures or follow-up
  • Concurrent participation in other clinical trials that may interfere with the outcomes of this study

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
介入・治療
Arm A: experimental sequence of non-AI exertion followed by AI-assisted exertion
The goal is to test the within-operator effect associated with AI assistance by comparing the performance of the same junior sonographer before and after AI guidance, and to compare the performance of both AI-assisted and unaided junior sonographers with that of the standalone AI model.
Participants first undergo ultrasound scanning and diagnosis by a junior sonographer without AI assistance, followed by ultrasound scanning by the same sonographer with AI assistance.
Arm B: experimental sequence of AI-assisted exertion followed by non-AI exertion
The goal is to test the clinical utility of AI with minimized potential carry-over effects and recall bias caused by repeated examinations on the same patient, by comparing the performance of one junior sonographer with AI-assisted, with that of independent unaided junior sonographers, and by comparing the performance of both AI-assisted junior sonographers and another unaided ones with that of the standalone AI model.
Participants first undergo ultrasound scanning and diagnosis by a junior sonographer with AI assistance, followed by ultrasound scanning by another junior sonographer without AI assistance. The two junior sonographers are blinded to each other's scanning and assessment results.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Completeness of ultrasound feature acquisition
時間枠:Up to 7 days from completion of the study
The completeness of ultrasound feature acquisition will be assessed with reference to national authoritative quality-control standards. After each examination, all stored ultrasound images and videos will be labeled according to their intended purpose. A feature will be considered adequately acquired when at least one stored image or video provides sufficient visual evidence for assessment of that feature. The proportion of required features successfully acquired will be calculated. The proportion of redundant stored images will also be recorded as an additional indicator of acquisition quality.
Up to 7 days from completion of the study
Accuracy of interpretation of individual ultrasound features
時間枠:Up to 7 days from completion of the study
The accuracy of interpretation of ultrasound features will be assessed by comparing the assessments made by junior sonographers under AI-assisted and unassisted conditions with the findings independently acquired and interpreted by expert sonographers during a separate repeat ultrasound examination. The accuracy rate for each feature will be calculated.
Up to 7 days from completion of the study
Agreement between junior and expert sonographers in ultrasound diagnosis
時間枠:Up to 7 days from completion of the study
Agreement between junior and expert sonographers will be assessed for the final diagnosis of ovarian lesions. The assessments made by junior sonographers under AI-assisted and unassisted conditions will be compared with the corresponding diagnoses independently obtained by expert sonographers during a separate repeat ultrasound examination, which will then be quantified using appropriate agreement statistics.
Up to 7 days from completion of the study
Diagnostic accuracy of ovarian tumors
時間枠:Within 3 months after the ultrasonography examination
Diagnostic accuracy will be assessed against histopathological diagnosis as the golden reference standard. This outcome will be evaluated only in participants who undergo surgical treatment and have definitive histopathological findings based on paraffin-embedded surgical specimens.
Within 3 months after the ultrasonography examination
Diagnostic performance of ovarian tumors
時間枠:Within 3 months after the ultrasonography examination
Area under curve will be assessed against histopathological diagnosis as the golden reference standard. This outcome will be evaluated only in participants who undergo surgical treatment and have definitive histopathological findings based on paraffin-embedded surgical specimens.
Within 3 months after the ultrasonography examination
Diagnostic performance of ovarian tumors
時間枠:Within 3 months after the ultrasonography examination
Diagnostic sensitivity and specificity will be assessed against histopathological diagnosis as the golden reference standard. This outcome will be evaluated only in participants who undergo surgical treatment and have definitive histopathological findings based on paraffin-embedded surgical specimens.
Within 3 months after the ultrasonography examination
Diagnostic performance of ovarian tumors
時間枠:Within 3 months after the ultrasonography examination
Diagnostic F1-score will be assessed against histopathological diagnosis as the golden reference standard. This outcome will be evaluated only in participants who undergo surgical treatment and have definitive histopathological findings based on paraffin-embedded surgical specimens.
Within 3 months after the ultrasonography examination

二次結果の測定

結果測定
メジャーの説明
時間枠
Confidence in ultrasound feature acquisition and diagnosis
時間枠:Up to 7 days from completion of the study
Sonographers' confidence in the completeness and adequacy of feature acquisition and in their final diagnostic assessment will be evaluated using a predefined rating scale as follows: 5 = very confident, 4 = confident, 3 = uncertain, 2 = less confident, and 1 = not confident at al.
Up to 7 days from completion of the study

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年8月19日

一次修了 (推定)

2027年3月31日

研究の完了 (推定)

2027年3月31日

試験登録日

最初に提出

2026年8月17日

QC基準を満たした最初の提出物

2026年9月2日

最初の投稿 (実際)

2026年9月3日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月3日

QC基準を満たした最後の更新が送信されました

2026年9月2日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • IRB-20250490-R

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する